Giuseppe (J) TRITTO2 and Sujoy GUHA1
1School of Medical Science and Technology, Indian Institute of Technology, India
2WABT ΓΆΒ?Β? World Academy of BioMedical Sciences and Technologies, UNESCO NGOs House (c/o Insula), France
HealthLife Creative Enterprise, Science Park, Brun
Posters-Accepted Abstracts: J Cancer Sci Ther
Using the compound Styrene maleic anhydride (SMA) as a model of a drug, a novel approach for sustainedendogenously formed liposome encapsulated drug delivery to the prostate gland has been designed. Intra vas deferens depotof a combination of high molecular weight SMA (SMAh, the drug) and low molecular weight SMA (SMAl) is formedby one time injection. The SMAh breaks down sperm membrane to provide a continuous supply of phospholipids macrocomplexes ΓΆΒ?Β? as mesosomes ΓΆΒ?Β? from the sperm.The SMAl forms cleavage centers causing slow breakaway of nanoSMAh fragments, as nanoliposomes ΓΆΒ?Β? nanosomes.Vas peristaltic activity and fluidic pressure provide the mechanical forces bringing reactants together leading to natural encapsulation of nano particles of SMAh within phospholipids shells giving a continuous supply of sperm-derived nanoliposomes. A dimethyl sulphoxide (DMSO) constituent of the depotleads to the sulfur attachment on the new generated liposomes, accounting of the nanosomes passage through the vas deferens ΓΆΒ?Β? prostate barrier by a prostate tissue sulfur affinity mechanism. The BioConcept has been tested by implantation of the SMA in the rat vas deferens: formation of nanoliposomesin vivo; actual encapsulation of SMA within the liposome; the overall DrugEncapsulation Efficiency; thepresence of liposomes in the vas deferens fluid and transfer to the prostate have been confirmedby Transmission Electron Microscope (TEM) examination and Fluorescence Microscopy following Nile Red staining ofvas fluid and prostate tissue. This full chemical process has been patented Internationally (Patent granted EP 2268290). The First Designed Drugs ΓΆΒ?Β? RISUG and RISUG Adv ΓΆΒ?Β? have been applied on large scale as Reversible Contraceptive Method in Males in India, under the aegis of the Ministery of Health and the Society of Andrology of India ΓΆΒ?Β? SAI, and are currently tested in some European Countries on an official European clinical trial, directed by Prof. Giuseppe Tritto. With increasing longevity greater numbers of males are coming into the age group of high incidence of BPH and of prostate cancer. Therefore preventive solutions are of major interest. The potentially of linking drugs as finasteride to the nanoliposomial complex has been explored, due to the unique capability to generate Nanoliposomes inside the vas deferens with the specific property to cross through the vas deferens-prostate barrier: a continual formation of drug encapsulated nanosome is obtained. This innovative solution opens new possibilities in preventative and regenerative medicine in the major pathologies of the prostate and in the management of early stages and localized prostate cancer. Keywords: Styrene maleic anhydride, molecular weight, phospholipids, transport, vas deferens, prostate, liposomenanosome, sperm, electron microscopy, fluorescence microscopy and finasteride.
Cancer Science & Therapy received 5282 citations as per Google Scholar report
Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi 